menu

Loading...

NYXH Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

4.170

Open

4.170

VWAP

4.07

Vol

36.31K

Mkt Cap

172.97M

Low

4.010

Amount

147.66K

EV/EBITDA(TTM)

--

Total Shares

43.03M

EV

161.45M

EV/OCF(TTM)

--

P/S(TTM)

24.72

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

Show More

Events Timeline

(ET)

2026-02-18

16:30:00

Nyxoah Signs MoU with UAE Hospital for Genio Therapy

2026-01-21 (ET)

2026-01-21

16:30:00

Nyxoah Invests in Belgium to Expand Manufacturing Capacity

2026-01-12 (ET)

2026-01-12

16:20:00

Nyxoah Reports Preliminary FY25 Gross Revenue of EUR 11M

2025-12-17 (ET)

2025-12-17

05:20:00

Nyxoah Successfully Launches Genio System in the Netherlands

2025-11-26 (ET)

2025-11-26

05:30:47

Nyxoah Secures Higher Medicare Reimbursement for Genio

News

Newsfilter

02-27Newsfilter

Nyxoah Receives Transparency Notification from Robert Taub

Newsfilter

02-25Newsfilter

Nyxoah SA Discloses Voting Rights and Share Information

seekingalpha

01-14seekingalpha

Nyxoah (NYXH) Projects 25% Revenue Growth for Q1 2026

NASDAQ.COM

01-13NASDAQ.COM

Nyxoah Expects 348% Q4 Revenue Growth, $5.7M Forecast

NASDAQ.COM

01-13NASDAQ.COM

FibroBiologics (FBLG) Stock Rises 7.68%, Attracts Market Attention

Globenewswire

01-12Globenewswire

Nyxoah Receives 3.28% Shareholding Notification from BNP Paribas Asset Management

5 Analyst Rating

Wall Street analysts forecast NYXH stock price to rise

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

5.82

Averages

10.41

High

13.00

Current: 0.000

Low

5.82

Averages

10.41

High

13.00

Stifel

Jonathan Block

Buy

downgrade

$12 -> $11

AI Analysis

2026-01-29

Reason

Stifel

Jonathan Block

Price Target

$12 -> $11

AI Analysis

2026-01-29

downgrade

Buy

Reason

Stifel analyst Jonathan Block lowered the firm's price target on Nyxoah to $11 from $12 and keeps a Buy rating on the shares as part of the firm's Animal Health, Sleep, and Vision overview for 2026.

Baird

Neutral

downgrade

2025-12-16

Reason

Baird

Price Target

2025-12-16

downgrade

Neutral

Reason

Baird lowered the firm's price target on Nyxoah to EUR 5 from EUR 7 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees "several potential paths to improved" share performance for the group in 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NYXH

Unlock Now

Valuation Metrics

The current forward P/E ratio for Nyxoah SA (NYXH.O) is -1.80, compared to its 5-year average forward P/E of -5.95. For a more detailed relative valuation and DCF analysis to assess Nyxoah SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.95

Current PE

-1.80

Overvalued PE

-0.57

Undervalued PE

-11.33

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-5.13

Current EV/EBITDA

-1.69

Overvalued EV/EBITDA

-0.43

Undervalued EV/EBITDA

-9.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

39.37

Current PS

7.36

Overvalued PS

83.25

Undervalued PS

-4.50

Financials

AI Analysis

Annual

Quarterly

Whales Holding NYXH

Trading Trends

People Also Watch

Frequently Asked Questions

What is Nyxoah SA (NYXH) stock price today?

The current price of NYXH is 4.02 USD — it has decreased -1.47

What is Nyxoah SA (NYXH)'s business?

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

What is the price predicton of NYXH Stock?

Wall Street analysts forecast NYXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NYXH is10.41 USD with a low forecast of 5.82 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Nyxoah SA (NYXH)'s revenue for the last quarter?

Nyxoah SA revenue for the last quarter amounts to 1.97M USD, increased 55.77

What is Nyxoah SA (NYXH)'s earnings per share (EPS) for the last quarter?

Nyxoah SA. EPS for the last quarter amounts to -0.63 USD, increased 26.00

How many employees does Nyxoah SA (NYXH). have?

Nyxoah SA (NYXH) has 147 emplpoyees as of March 03 2026.

What is Nyxoah SA (NYXH) market cap?

Today NYXH has the market capitalization of 172.97M USD.